معرفی
Douglas Hanlon is a Research Scientist in the Department of Dermatology at Yale School of Medicine, specializing in immunotherapy and dendritic cell research. His work focuses on developing novel approaches for cancer treatment through extracorporeal engineering of immunostimulatory dendritic cell vaccines and nanotechnology platforms for antigen delivery.
- PhD from SUNY Health Science Center (1992)
- Postdoctoral Associate at Yale University School of Medicine (1995-1998)
Dr. Hanlon's research centers on dendritic cell-based immunotherapies for cancer treatment. His laboratory has developed methodologies to rapidly differentiate physiological dendritic cells directly from human or murine blood samples. His work includes developing biodegradable polymer nanoparticles for antigen delivery, particularly focusing on PLGA-based systems that can encapsulate tumor-associated antigens. His research spans multiple cancer types including melanoma, ovarian cancer, and squamous cell carcinoma, with recent expansion into applications for infectious diseases like SARS-CoV-2.
Analysis of Dr. Hanlon's recent publications reveals a strong focus on dendritic cell biology, immunogenic cell death, and nanoparticle-based delivery systems. His work demonstrates consistent innovation in developing rapid methods for dendritic cell production and novel approaches to enhance antigen presentation. The research spans fundamental immunology, translational applications, and clinical implementation, with particular emphasis on extracorporeal photochemotherapy and transimmunization approaches.
Dr. Hanlon's laboratory has received significant funding, including a 3-year Gates Foundation collaboration with the Santangelo lab at Emory/GT focusing on lipid nanoparticle-based delivery systems. His research is highly collaborative, working with multiple departments at Yale including Immunobiology, Reproductive Immunology, and Biomedical Engineering.
The Hanlon laboratory operates within the Lippard Laboratory of Clinical Investigation at Yale, where they continue to advance their work on dendritic cell vaccines and nanotechnology platforms for immunotherapy applications.
